Trials in Rhode Island.

This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…

This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…

This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…

This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…

This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…

This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…

This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…

This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…

This trial tests two versions of a healthy-living education program aimed at helping middle-aged adults make lasting lifestyle changes — better diet, more…

This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…

This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…

This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…

This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…

This is an observational study, meaning no drug or treatment is given. Researchers follow families with a rare inherited gene mutation that causes Alzheimer's,…

This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…

This trial tests several investigational drugs, including gantenerumab, solanezumab, E2814 and lecanemab, against placebo. It asks whether they slow cognitive…

This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…

This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…

This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…

LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…

PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…

This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…

This trial is testing emtricitabine — an HIV antiviral drug — as a possible intervention for people who already have biomarker-confirmed MCI or mild to…

This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…

This trial tests two investigational drugs, E2814 and lecanemab, in people who carry a gene mutation that causes early-onset Alzheimer's. It measures changes…

This trial is comparing two different PET scan tracers — Flortaucipir and MK-6240 — that are used to measure tau tangles in the brain, a hallmark of…

This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…

This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…

This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…

This trial is testing CT1812, an experimental drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia confirmed by…

This trial tests whether IGC-AD1, a twice-daily oral THC-based medication, can ease agitation in people with mild to severe Alzheimer's dementia. Agitation…

This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2)…

This is an observational study, meaning no drug or treatment is being given. Researchers will follow people with CADASIL, a rare inherited small-vessel brain…

This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…

This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…

This trial tests whether a once-daily 10 mg pill called Xanamem can safely affect thinking and daily function in people who already have mild or moderate…

This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…

This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…

This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already…

This is a data-gathering study, not a drug trial. Researchers are collecting blood, spinal fluid, eye, digital, MRI and PET scan data from older adults to see…

This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…

This trial tests remternetug, an anti-amyloid antibody drug, in people who carry a gene mutation that causes early-onset Alzheimer's and who still have normal…

This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…

This trial tests whether buntanetap, a daily pill, slows memory and thinking decline and helps everyday function in adults 55 to 85 with early Alzheimer's. It…

This trial tests ONO-2020, an experimental pill that works on gene regulation, in people already diagnosed with mild to moderate Alzheimer's. Researchers want…

This Phase 2 platform trial is testing tau-targeting drugs, called AADvac1 and Tau2, alone or combined with the anti-amyloid drug donanemab, in people aged 50…

This trial is testing KarXT plus KarX-EC, a combination drug approach aimed at improving cognition in people who already have mild to moderate Alzheimer's…

This trial is testing AADvac1, a vaccine designed to target tau protein, a key driver of Alzheimer's damage. It tests AADvac1 alone and combined with…